We are live on ! Find out more
AACP

Advantage Alpha Capital Partners Portfolio holdings

AUM $332M
1-Year Est. Return 12.78%
This Fund
S&P 500
This Quarter Est. Return
+6.59%
1 Year Est. Return
+12.78%
3 Year Est. Return
+79.23%
5 Year Est. Return
+110.24%
10 Year Est. Return
AUM
$532M
AUM Growth
+$3.37M
Cap. Flow
-$21.9M
Cap. Flow %
-4.12%
Top 10 Hldgs %
19.66%
Holding
164
New
10
Increased
32
Reduced
116
Closed
6

Sector Composition

Rank Sector Weight
1 Industrials 33.01%
2 Technology 18.11%
3 Healthcare 11.34%
4 Consumer Discretionary 11.28%
5 Financials 10.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
APG icon
76
APi Group
APG
$17.2B
$3.08M 0.58%
+117,545
New +$2.74M
CERT icon
77
Certara
CERT
$1.27B
$2.94M 0.55%
164,629
+3,028
+2% +$52.2K
CNM icon
78
Core & Main
CNM
$8.05B
$2.79M 0.53%
48,798
-42,726
-47% -$1.96M
PCOR icon
79
Procore
PCOR
$9.68B
$2.75M 0.52%
33,473
-3,100
-8% -$230K
EYE icon
80
National Vision
EYE
$1.37B
$2.73M 0.51%
123,060
-108,589
-47% -$2.29M
HLIO icon
81
Helios Technologies
HLIO
$2.41B
$2.63M 0.49%
58,840
+16,890
+40% +$725K
GWRE icon
82
Guidewire Software
GWRE
$17.1B
$2.57M 0.48%
22,055
-27,968
-56% -$3.2M
MGNI icon
83
Magnite
MGNI
$3.4B
$2.55M 0.48%
237,217
-268,438
-53% -$2.68M
AIN icon
84
Albany International
AIN
$1.66B
$2.52M 0.47%
26,956
-27,278
-50% -$2.5M
EB
85
DELISTED
Eventbrite
EB
$2.52M 0.47%
459,754
-120,718
-21% -$875K
PAY icon
86
Paymentus
PAY
$4.53B
$2.44M 0.46%
107,288
-38,276
-26% -$690K
AGL icon
87
Agilon Health
AGL
$1.55B
$2.31M 0.43%
15,144
-1,352
-8% -$225K
LESL icon
88
Leslie's
LESL
$4.97M
$2.22M 0.42%
17,113
+2,524
+17% +$361K
VCEL icon
89
Vericel Corp
VCEL
$2.1B
$1.3M 0.24%
24,988
-8,888
-26% -$390K
TRDA icon
90
Entrada Therapeutics
TRDA
$273M
$1.29M 0.24%
91,116
-14,021
-13% -$198K
ADMA icon
91
ADMA Biologics
ADMA
$2.09B
$1.22M 0.23%
+184,466
New +$1.01M
IRWD icon
92
Ironwood Pharmaceuticals
IRWD
$682M
$1.14M 0.21%
130,966
+5,261
+4% +$63.8K
VYGR icon
93
Voyager Therapeutics
VYGR
$218M
$1.14M 0.21%
122,311
-54,560
-31% -$461K
ORGO icon
94
Organogenesis Holdings
ORGO
$224M
$1.12M 0.21%
+396,116
New +$1.35M
VCYT icon
95
Veracyte
VCYT
$3.48B
$1.12M 0.21%
50,534
+4,409
+10% +$108K
HALO icon
96
Halozyme
HALO
$12B
$1.1M 0.21%
27,079
-2,838
-9% -$106K
DVAX
97
DELISTED
Dynavax Technologies
DVAX
$1.1M 0.21%
88,683
-404
-0.5% -$5.27K
MDXG icon
98
MiMedx Group
MDXG
$656M
$1.08M 0.2%
139,893
-17,812
-11% -$143K
ACLX
99
DELISTED
Arcellx
ACLX
$1.08M 0.2%
15,475
-7,198
-32% -$456K
ALKS icon
100
Alkermes
ALKS
$7.95B
$1.06M 0.2%
39,008
-10,522
-21% -$299K

Similar funds

Advantage Alpha Capital Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Advantage Alpha Capital Partners held 164 positions worth $532M, up 0.64% from $528M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Advantage Alpha Capital Partners withdrew a net $21.9M in Q1 2024, closing 6 positions and reducing 116 holdings. Its most notable exit was RXO, an estimated $4.7M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 33% of assets, up from 30% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Advantage Alpha Capital Partners opened a new position in Clarivate worth $7.84M.

  • Advantage Alpha Capital Partners's largest Q1 2024 buy was Clarivate: 1,055,852 shares worth $7.84M.
  • Advantage Alpha Capital Partners added most to Fox Factory Holding Corp in Q1 2024, an estimated $8.21M increase.
  • Advantage Alpha Capital Partners's biggest Q1 2024 reduction was HubSpot, cutting an estimated $5.61M.
  • Advantage Alpha Capital Partners fully exited RXO in Q1 2024, selling an estimated $4.7M.
  • Advantage Alpha Capital Partners's ten largest holdings make up 20% of its $532M portfolio in Q1 2024.
  • Advantage Alpha Capital Partners opened 10 new positions and closed 6 in Q1 2024.
  • Advantage Alpha Capital Partners's portfolio value rose 0.64% quarter-over-quarter to $532M.

Based on Advantage Alpha Capital Partners's 13F filing for Q1 2024, filed 13 May 2024.